PYRIDOSTIGMINE BROMIDE tablet

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNII:19QM69HH21)

Saadav alates:

Bryant Ranch Prepack

INN (Rahvusvaheline Nimetus):

PYRIDOSTIGMINE BROMIDE

Koostis:

PYRIDOSTIGMINE BROMIDE 60 mg

Retsepti tüüp:

PRESCRIPTION DRUG

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE TABLET
BRYANT RANCH PREPACK
----------
PYRIDOSTIGMINE BROMIDE TABLETS, USP
RX ONLY
DESCRIPTION
Pyridostigmine bromide tablets, USP are an orally active
cholinesterase inhibitor. Chemically,
pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide
dimethylcarbamate. Its structural
formula is:
Pyridostigmine bromide, USP is a white or almost white crystalline,
deliquescent powder. It is very
soluble in water and in alcohol, slightly soluble in hexane,
practically insoluble in ether.
Each pyridostigmine bromide tablet, USP intended for oral
administration contains 60 mg of
pyridostigmine bromide, USP. In addition, each tablet contains the
following inactive ingredients:
anhydrous lactose, colloidal silicon dioxide, low substituted
hydroxypropyl cellulose, silicon dioxide
and stearic acid.
CLINICAL PHARMACOLOGY
Pyridostigmine bromide inhibits the destruction of acetylcholine by
cholinesterase and thereby permits
freer transmission of nerve impulses across the neuromuscular
junction. Pyridostigmine is an analog of
neostigmine (Prostigmin
), but differs from it in certain clinically significant respects; for
example,
pyridostigmine is characterized by a longer duration of action and
fewer gastrointestinal side effects.
INDICATIONS AND USAGE
Pyridostigmine bromide tablets, USP are useful in the treatment of
myasthenia gravis.
CONTRAINDICATIONS
Pyridostigmine bromide tablets, USP are contraindicated in mechanical
intestinal or urinary obstruction,
and particular caution should be used in its administration to
patients with bronchial asthma. Care should
be observed in the use of atropine for counteracting side effects, as
discussed below.
WARNINGS
Although failure of patients to show clinical improvement may reflect
underdosage, it can also be
®#
indicative of overdosage. As is true of all cholinergic drugs,
overdosage of pyridostigmine bromide
may result in cholinergic crisis, a state characterized by increasing
muscle weakness which, through
involvement of the muscle